TSHA — Taysha Gene Therapies, Inc. stock price, charts and financials
QT61Taysha Gene Therapies, Inc.Taysha Gene Therapies, Inc. (NASDAQ: TSHA) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
Latest market price
6.46
-0.10-1.45%
TA
Loading chart...
Snapshot
| Index | - | P/E | - | EPS (ttm) | -0.36 | Insider Own | 10.77% | Shs Outstand | 319.86M | Perf Week | 11.95% |
| Market Cap | 2.10B | Forward P/E | - | EPS next Y | -0.46 | Insider Trans | -1.16% | Shs Float | 265.14M | Perf Month | -0.15% |
| Enterprise Value | 1.84B | PEG | 2.55 | EPS next Q | - | Inst Own | - | Short Float | 17.08% | Perf Quarter | -1.65% |
| Income | -113.31M | P/S | - | EPS this Y | -28.85% | Inst Trans | - | Short Ratio | 14.03 | Perf Half Y | 48.75% |
| Sales | 7.47M | P/B | 11.35 | EPS next Y | 1.26% | ROA | -43.24% | Short Interest | 45.29M | Perf YTD | 19.27% |
| Book/sh | - | P/C | - | EPS next 5Y | - | ROE | -56.07% | 52W High | 7.19 -10.14% | Perf Year | 135.13% |
| Cash/sh | - | P/FCF | - | EPS past 3/5Y | - | ROIC | -47.30% | 52W Low | 2.65 143.87% | Perf 3Y | 866.41% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | 49.38% - | Gross Margin | 88.22% | Volatility | 5.08% 7.10% | Perf 5Y | -62.06% |
| Dividend TTM | - | EV/Sales | - | EPS Y/Y TTM | 0.00% | Oper. Margin | -1774.37% | ATR (14) | 0.38 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 14.04 | Sales Y/Y TTM | 0.00% | Profit Margin | -1738.40% | RSI (14) | 60.37 | Recom | 2.17 |
| Dividend Gr. 3/5Y | - | Current Ratio | 14.04 | EPS Q/Q | -50.00% | SMA20 | 11.99% | Beta | 1.25 | Target Price | 14.00 |
| Payout | 0.00% | Debt/Eq | 0.08 | Sales Q/Q | -100.00% | SMA50 | 8.85% | Rel Volume | 0.64 | Prev Close | 6.56 |
| Employees | 99 | LT Debt/Eq | 0.07 | Earnings | Aug 11 | SMA200 | 24.13% | Avg Volume | 3.03M | Price | 6.46 |
| IPO Date | Sep 24, 2020 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -24.14% - | Net Debt/EBITDA | 2.00 | Volume | 1,929,504 | Change | -1.45% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Jul-21-26 | Reiterated | Goldman Sachs | Buy | $11 → $13 |
| Jun-30-26 | Reiterated | Robert W. Baird | $12 → $15 | |
| Jun-23-26 | Reiterated | Pivotal Research | $10 → $14 | |
| Jan-06-26 | Reiterated | Raymond James | $9.00 → $13 | |
| Jan-05-26 | Reiterated | Wells Fargo | Overweight | $11 |
| Dec-04-25 | Reiterated | Goldman Sachs | Neutral | $11 |
| Dec-04-25 | Reiterated | UBS | $11 | |
| Nov-14-25 | Reiterated | Cantor Fitzgerald | Overweight | $13 |
| Nov-05-25 | Reiterated | JMP Securities | Market Outperform | $6.00 → $8.00 |
| Oct-02-25 | Reiterated | Robert W. Baird | $7.00 → $12 |
Latest News
Aug-07-26
Aug-07-2608:00AM
Aug-04-26
Aug-04-2604:00PM
Aug-03-26
Aug-03-2608:00AM
Jul-21-26
Jul-21-2608:43AM
Jul-02-26
Jul-02-2602:33PM
Jun-30-26
Jun-30-2609:38AM
Jun-26-26
Jun-25-26
Jun-25-2608:01PM
08:08AM
05:08AM
02:33AM
Jun-24-26
04:03PM
Jun-23-26
Company
Taysha Gene Therapies, Inc. is a biotech firm specializing in the creation and market introduction of gene therapies that utilize adeno-associated virus (AAV) vectors. Its core mission is to tackle inherited diseases affecting the central nervous system (CNS). The company's development pipeline features several key programs: TSHA-120 is aimed at giant axonal neuropathy; TSHA-102 is in development for Rett syndrome; TSHA-121 and TSHA-118 are both being advanced for CLN1 disease; TSHA-105 addresses SLC13A5 Deficiency; and TSHA-101 targets GM2 gangliosidosis. Furthermore, Taysha has forged a strategic alliance with The University of Texas Southwestern Medical Center to jointly advance and bring to market innovative gene therapy solutions. Founded in 2019, the company operates from its headquarters in Dallas, Texas.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 8 | 10 | 8 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 0 | 0 | 0 | — | — | — | — | — | |
| Gross Profit | 8 | 10 | 8 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 32 | 34 | 29 | — | — | — | — | — | |
| Research and Development | 66 | 86 | 66 | — | — | — | — | — | |
| Other Operating Expense | 5 | 0 | 5 | — | — | — | — | — | |
| Operating Income | -94 | -110 | -91 | — | — | — | — | — | |
| Interest Expense | 0 | 0 | 0 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 1 | 2 | 2 | — | — | — | — | — | |
| Net Income Before Taxes | -94 | -109 | -89 | — | — | — | — | — | |
| Income Taxes | 0 | 0 | 0 | — | — | — | — | — | |
| Consolidated Net Income | -94 | -109 | -89 | — | — | — | — | — | |
| Net Income From Continuing Operations | -94 | -109 | -89 | — | — | — | — | — | |
| Net Income | -94 | -109 | -89 | — | — | — | — | — | |
| EPS (Recurring) | -0.36 | -0.34 | -0.36 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -0.36 | -0.34 | -0.36 | — | — | — | — | — | |
| EPS (Diluted) | -0.36 | -0.34 | -0.36 | — | — | — | — | — | |
| EBITDA | -91 | -108 | -88 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 240.82 | 176.00 | 54.06 | — | — | — | — | — | |
| Gross Margin | 100.00 | 100.00 | 100.00 | — | — | — | — | — | |
| Operating Margin | -1,175.00 | -1,100.00 | -1,137.50 | — | — | — | — | — | |
| Net Margin | -1,175.00 | -1,090.00 | -1,112.50 | — | — | — | — | — | |
| Shares Outstanding | 298 | 320 | 250 | — | — | — | — | — | |
| Market Capitalization | 1,927 | 1,760 | 433 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Nagendran Sukumar | President and Head of R&D | Jul 10 '26 | Sale | 6.24 | 200,000 | 1,248,000 | 936,410 | Jul 10 |
| Nagendran Sukumar | President and Head of R&D | Apr 10 '26 | Option Exercise | 1.71 | 19,021 | 32,526 | 1,336,410 | Apr 13 |
| Nagendran Sukumar | President and Head of R&D | Apr 10 '26 | Sale | 4.46 | 200,000 | 892,000 | 1,136,410 | Apr 13 |
| Alam Kamran | CHIEF FINANCIAL OFFICER | Feb 04 '26 | Sale | 4.52 | 1,655 | 7,481 | 1,442,131 | Feb 06 |
| Nolan Sean P. | Chief Executive Officer | Jan 26 '26 | Sale | 4.61 | 41,312 | 190,448 | 2,908,257 | Jan 27 |
| Nagendran Sukumar | President and Head of R&D | Jan 26 '26 | Sale | 4.61 | 26,918 | 124,092 | 1,317,389 | Jan 27 |
| Alam Kamran | CHIEF FINANCIAL OFFICER | Jan 26 '26 | Sale | 4.61 | 23,849 | 109,944 | 1,443,786 | Jan 27 |
| Nolan Sean P. | Chief Executive Officer | Jan 23 '26 | Sale | 4.75 | 136,789 | 649,748 | 2,949,569 | Jan 27 |
| Nagendran Sukumar | President and Head of R&D | Jan 23 '26 | Sale | 4.75 | 89,132 | 423,377 | 1,344,307 | Jan 27 |
| Alam Kamran | CHIEF FINANCIAL OFFICER | Jan 23 '26 | Sale | 4.75 | 78,968 | 375,098 | 1,467,635 | Jan 27 |
| Nagendran Sukumar | President and Head of R&D | Jan 12 '26 | Option Exercise | 1.15 | 200,000 | 229,440 | 1,206,439 | Jan 14 |
| Nagendran Sukumar | President and Head of R&D | Jan 12 '26 | Sale | 4.71 | 200,000 | 942,000 | 1,006,439 | Jan 14 |
| Nagendran Sukumar | President and Head of R&D | Dec 01 '25 | Option Exercise | 1.71 | 260,047 | 444,680 | 1,266,486 | Dec 01 |
| Nagendran Sukumar | President and Head of R&D | Dec 01 '25 | Sale | 4.51 | 260,047 | 1,172,812 | 1,006,439 | Dec 01 |
| Nagendran Sukumar | President and Head of R&D | Nov 28 '25 | Option Exercise | 1.07 | 110,125 | 117,363 | 1,116,564 | Dec 01 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.